Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey

Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective... Virchows Arch (2017) 471:809–813 DOI 10.1007/s00428-017-2222-z BRIEF REPORT Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey 1 1 2 3 Zandra C. Deans & Hannah Williams & Elisabeth M. C. Dequeker & Cleo Keppens & 4 5 6 6 Nicola Normanno & Ed Schuuring & Simon J. Patton & Melanie Cheetham & 7 8,9 Rachel Butler & Jacqueline A. Hall & On behalf of IQN Path ASBL Received: 18 April 2017 /Revised: 6 July 2017 /Accepted: 14 August 2017 /Published online: 25 August 2017 The Author(s) 2017. This article is an open access publication Introduction several advantages: in the absence of suitable or sufficient tissue biopsy, it yields material for molecular analysis, can demonstrate Molecular biomarker analysis for the personalised treatment molecular resistance to targeted treatment and is an alternative to of non-small cell lung cancer (NSCLC) and colorectal cancer invasive tissue sampling [4]. Plasma ctDNA analysis may also (CRC) is becoming more common, due to the number and prove useful in cases of intra- and inter-tumour heterogeneity availability of molecular targets for predictive biomarker test- [5]. With formal approval from the European Medicine Agency ing http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Virchows Archiv Springer Journals

Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey

Download PDF
5 pages

Loading next page...
 
/lp/springer_journal/review-of-the-implementation-of-plasma-ctdna-testing-on-behalf-of-iqn-LU0pKWVBhh

References (13)

Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Pathology
ISSN
0945-6317
eISSN
1432-2307
DOI
10.1007/s00428-017-2222-z
pmid
28840321
Publisher site
See Article on Publisher Site

Abstract

Virchows Arch (2017) 471:809–813 DOI 10.1007/s00428-017-2222-z BRIEF REPORT Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey 1 1 2 3 Zandra C. Deans & Hannah Williams & Elisabeth M. C. Dequeker & Cleo Keppens & 4 5 6 6 Nicola Normanno & Ed Schuuring & Simon J. Patton & Melanie Cheetham & 7 8,9 Rachel Butler & Jacqueline A. Hall & On behalf of IQN Path ASBL Received: 18 April 2017 /Revised: 6 July 2017 /Accepted: 14 August 2017 /Published online: 25 August 2017 The Author(s) 2017. This article is an open access publication Introduction several advantages: in the absence of suitable or sufficient tissue biopsy, it yields material for molecular analysis, can demonstrate Molecular biomarker analysis for the personalised treatment molecular resistance to targeted treatment and is an alternative to of non-small cell lung cancer (NSCLC) and colorectal cancer invasive tissue sampling [4]. Plasma ctDNA analysis may also (CRC) is becoming more common, due to the number and prove useful in cases of intra- and inter-tumour heterogeneity availability of molecular targets for predictive biomarker test- [5]. With formal approval from the European Medicine Agency ing

Journal

Virchows Archiv – Springer Journals

Published: Aug 25, 2017

There are no references for this article.